Sangart Raises $50M

San Diego-based Sangart, a firm developing products to prevent and treat ischemia and to stabilize the hemoglobin of sickle cell disease patients, said Tuesday that it has raised $50M in a Series G equity financing round. The round was led by Leucadia National Corporation. The company said the funding brings its total raised to more than $230M since 1998. Sangart also said the round included warrants, which if exercise, could provide up to $50M in future funding. The company said the funding will go to advance development of its MP4OX product in severe traumatic hemorrhage and the MP4CO product in sickle cell disease. More information »